2024

Nanaologica Receives Order on NLAB Saga® Valued at approx. SEK 1,9 Million from Returning Customer in China Nanologica has received another order for the company’s silica-based purification media NLAB Saga® from a returning customer in China. This is the fourth order since June from this customer who uses NLAB Saga® in the production of a GLP-1 analogue. “The fact that this customer is now placing another order for NLAB Saga® confirms once again that our

FINANCIAL SUMMARY Net sales for the third quarter amounted to SEK 611 thousand (342) and for the nine-month period to SEK 7,822 thousand (1,368) Operating loss for the quarter amounted to SEK -22,203 thousand (-10,292) and for the nine-month period to SEK -47,365 thousand (-34,324) Loss before tax for the quarter amounted to SEK -23,701 thousand (-11,554) and for the nine-month period to SEK -51,561 thousand (-38,318) Earnings per share before and after dilution were

Nanologica AB (publ) (“Nanologica” or the “Company”) today announces the outcome of the Company’s rights issue of approximately SEK 99.4 million (the “Rights Issue”), for which the subscription period ended on October 14, 2024. The Rights Issue concerns so-called units, consisting of four shares and one free of charge warrant of series TO 2024/2025 (“Unit”). The Rights Issue has been subscribed to approximately 87.0 percent with and without the support of unit rights, of which

Nanologica has received an order for the company’s silica-based purification media NLAB Saga® from a customer in China. The order is the second order placed by this customer and the value of the new order amounts to approximately SEK 3.7 million. The customer is a pharmaceutical manufacturer that in June this year placed a first order for NLAB Saga® for production, after a period of evaluation of the product. Today’s order is thus the second